0-1	Date of Visit:	
Dr.	Subject ID:	

Follow Up Visits

	D	ate of Visit:			
□ Week 4	□ Week 8	□ Week 12	□ Week 24	□ Week 36	□ Week 48
	□ Week 60	☐ Week 72	□ Week 84	□ Week 96	
☐ Adverse Events					
☐ Concomitant M	edications		•		on was added to those activities visits. Now a third party will be
☐ Validated Invest	tigator's Assessme	ent (vIGA)			y was intentionally skipped.
☐ Eczema Area Se	verity Index (EASI)			
☐ Tanner Staging	(if applicable-Only	Week 24, 48, a	and 72) □ N/A		
☐ TB Risk Assessm	ent Form/ TB tes	t (Only on Week	< 48) □ N/A		
☐ Chest X-ray (On	ly on Week 48-if	applicable per T	B Risk Assessme	nt Form) 🛘 N/A	
☐ Vital Signs					
□ Physical Exam (Except week 8) □ N/A					
☐ 12 Lead ECG (Or	nly on Week 48) [N/A			
☐ Urinalysis					
☐ Urine pregnancy	test (if applicabl	e) 🗆 N/A			
☐ Blood Draw					
□ PK Samples (If applicable) □ N/A					
☐ Dosing Diary and Compliance Review					
☐ Dispense Study Drug					
☐ Dispense Home	Urine Pregnancy	Tests (if applica	ble) □ N/A		
☐ ClinCard					
☐ Scheduling					
☐ Requisition					
Pages 1 of 6	v. 01.9.2022			SC:Dat	e:

Date of Visit:	
Dr. Subject ID:	
Adverse Events	
Where there any changes to the patient's medical status? ☐ Yes ☐ No	The "N/A" (not applicable) option was added to those activities
If yes, was adverse events chart updated? ☐ Yes ☐ No ☐ N/A 1	which don't apply in all situations.
Concomitant Medications	2
Where there any changes to the patient's medications? ☐ Yes ☐ No 2	Guidance on obtaining vital signs was added to aid the coordinator.
If yes, was con meds chart updated? ☐ Yes ☐ No ☐ N/A 2	
Validated global Assessment (vIGA)	Modelling the format of
Was the assessment done? (separate form): ☐Yes ☐No	the time of vital assessment ensures consistency of data.
Eczema Area and Sensitivity Index (EASI)	
Was the assessment done? (separate form): \Box Yes \Box No	
Tanner Staging (Weeks 24, 48, and 72 Only)	
Was the assessment done? (separate form): \Box Yes \Box No \Box N/A \Box	
TB Risk Assessment Form (Only on Week 48)	
Was the Risk Assessment Form completed? (separate form): ☐ Yes ☐ No	□ N/A 1
Chest X-ray (only if applicable per TB Risk Assessment Form)	
Completed: Date/Time:	
<u>Vital Signs</u>	
-Obtain prior to blood collection and dosing 2	
Time of Vitals assessment (24:00):3	
Blood Pressure: mmHg	
Was the patient sitting for three minutes before taking blood pressure? \Box Ye	es □No 2
Where was blood pressure taken (specify side and location of body):	
Pulse: beats/min	
Respiratory Rate: breaths/min	
Temperature: □F □C	
Method of temperature collection: tympanic oral other:	2
-Ensure subject is wearing lightweight clothing and no shoes 2	
Weight: alb akg	
Height: pin pcm	
Pages 2 of 6 v. 01.9.2022 SC:Dat	e:

	Date of Visit:
Dr.	Subject ID:

Physical Exam

No changes were made to this page.

SC:_____Date: _____

		(Except Week 8)	No changes were made to thi
Date:/_		Time::	
Body System		Result	Abnormality
General Appearance	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Head, Neck, Ears, Nose, Throat, Eyes	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Dermatologic	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Cardiovascular	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Respiratory	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Abdomen	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Neurological	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Musculoskeletal	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Extremities	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Lymph Nodes	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
Other (specify):	☐ Normal ☐ Not Done significant	Abnormal, clinically significant Abnormal, not clinically	
PI Signature:		Date:	

ıbject ID:	TANKS OF STREET			
12-Lead ECG (Only on Week 48) N/A				
	\(1			
pine position for 5 minutes before	recording			
: Time of ECG::				
yyyy hh	mm (1		
1:	`	Guidance added to aid the coordinator.		
		the decidinator.		
nt				
Left Ventricular hypertrophy Right Ventricular hypertrophy Q wave abnormality ST segment depressed > +1mm ST egment elevated> =1mm	U wave a	bnormality bhormality blongation normality, specify:		
If QTcF prolongation, QTCF =msec (M: >430MSEC; F: >450MSEC) If QTCF prolongation, baseline =msec (prior to drug exposure)				
Date:_				
d?□Yes □ No □ N/A	(2 PI signature and date		
Time performed:: added as not prese past version. PREGNANCY TEST – IF APPLICABLE				
		added as not present in past version.		
Yes □ No □ N/A /_ mm yyyy		•		
Yes □ No □ N/A /	um □Urine	•		
ו ו	Time of ECG:: yyyy	Time of ECG::		

SC:_____Date: _____

Pages 4 of 6 v. 01.9.2022

		Date of Visit:		
	Dr.	Subject ID:		
	PK Sampling (If dose is modified based on analysis at subsequent visit.) (Sample will not be collected when decoupled to the			sit day and
	Was the blood draw perfo	ormed? □Yes □No □ N/A	: Dose not changed since last visi	1
	Time performed:			
			1	(()
	Drug Return			"NA" added.
	Were kits from prior visit returne	d? □ Yes □ No		
	If yes, what kits were returned? ()	please specify if kits were e	empty when returned)	
Г		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
L	If no, was patient/guardian remin	ided to bring kits at next vi	sit? □Yes □ No □ N/A	A new question to remind staff to
	Dosing Diary and Compliance	Review		remind participants
	Formulation: tablet (QD)	Solution (BID) 3		was added.
	Date & Time of second to last dos	se:		
	Date & Time of last dose:			Specific questions to record dosing added.
	Was Dosing Diary reviewed and si	igned by coordinator? □ Ye	es 🗆 No	
	Was new Dosing diary dispensed?	? □ Yes □ No		
	Compliance			4
	• Unit variance of 1 st bottle Unit variance (drug used). + +	+ unit variance of 2 nd bottl	le+ etc. (for totally # of bottles) ning-weight of bottle after return it variance)	An entire section on dosage compliance added, with significant detail regarding amount per bottle and
	=			daily dosage.
	 Average dose given per da 	ay / prescribed daily dose =	= % compliance	
	=	<u>%</u>		
	Was drug compliance reviewed w	ith patient/guardian of pat	tient? 🗆 Yes 🗆 No	
	Was patient between 80% and 12	.0% compliant? ☐ Yes ☐ No		
	If no, was patient re-educ	ated on drug compliance?	□ Yes □ No	
r	Dispense Drug (5)			5
	Was study drug dispensed and do -See dispensation confirmation an Was there a change is patient dos	nd copy of dispensed kits fo	1225 TO THE TOTAL TO THE T	Guidance added here regarding dosage
	Was there a change is patient dos Was patient/guardian instructed to Did patient/guardian verbalize un	to return all drug in possess		dispensation and to account for minors with parent/guardians.
	Pages 5 of 6 v. 01.9.2022		SC:Date:	

Date of Visit:		
Subject ID:		
tests dispensed? Yes		The "N/A" (not applicable) option was added to those activities which don't apply in all
cheduled? □Yes □No		situations.
nd time:		(2)
form filled out? □Yes □No	2	Guidance added to aid the coordinator.
	m filled out? □Yes □No	egnancy Tests Initial only) tests dispensed? Yes

SC:_____Date: _____